In human cancers, inactivation of E-cadherin, through mutation, promoter methylation, or transcriptional repression, is associated with epithelial to mesenchymal transition (EMT), progression from adenoma to carcinoma, and the acquisition of metastatic potential [12]–[16]. Here, CDH1 is linked to cancer.